Rankings
▼
Calendar
VCEL
Vericel Corporation
$2B
Q2 2018 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$19M
+12.1% YoY
Gross Profit
$11M
59.4% margin
Operating Income
-$4M
-22.3% margin
Net Income
-$5M
-24.5% margin
EPS (Diluted)
$-0.12
QoQ Revenue Growth
+5.5%
Cash Flow
Operating Cash Flow
-$5M
Free Cash Flow
-$6M
Stock-Based Comp.
$2M
Balance Sheet
Total Assets
$122M
Total Liabilities
$32M
Stockholders' Equity
$91M
Cash & Equivalents
$95M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$19M
$17M
+12.1%
Gross Profit
$11M
$9M
+21.6%
Operating Income
-$4M
-$3M
-68.4%
Net Income
-$5M
-$2M
-94.8%
Revenue Segments
Product
$19M
100%
← FY 2018
All Quarters
Q3 2018 →
VCEL Q2 2018 Earnings — Vericel Corporation Revenue & Financial Results | Market Cap Arena